{
    "clinical_study": {
        "@rank": "57205", 
        "arm_group": {
            "arm_group_label": "selinexor", 
            "arm_group_type": "Experimental", 
            "description": "selinexor at 50 mg/m2 oral twice weekly"
        }, 
        "brief_summary": {
            "textblock": "This is a single center, open-label, single arm Phase 2 clinical study of the oral Selective\n      Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in patients with metastatic\n      castration-resistant prostate cancer (CRPC)."
        }, 
        "brief_title": "Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, open-label study to explore the effect of selinexor (KPT-330) therapy in\n      patients with metastatic castration-resistant prostate cancer (CRPC). Approximately 50\n      patients are planned for enrollment.  Patients will receive an initial oral dose of\n      selixenor at 50 mg/m2 oral twice weekly (e.g Monday/Wednesday) per cycle.  Each cycle is 28\n      days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven adenocarcinoma of the prostate with evidence for skeletal\n             metastases on bone scan and/or CT scan.\n\n          -  Must have received one agent known to impact survival (abiraterone, enzalutamide,\n             ect.)\n\n          -  Eastern Cooperative Oncology Group (ECOG) < 2\n\n          -  Serum testosterone levels < 50ng/ml\n\n          -  Ongoing gonadal androgen deprivation therapy with LHRH analogues or orchiectomy.\n             Patients, who have not had an orchiectomy, must be maintained on standard dosing of\n             LHRH analogue therapy at appropriate frequency for the duration of the study\n\n          -  Progression of disease despite androgen ablation (either documented osseous or soft\n             tissue metastatic disease progression or by PSA criteria progression).  Progressive\n             disease will be defined by PSA evidence: a PSA level of at least 5 ng/ml which has\n             risen on at least 2 successive occasions, at least 2 weeks apart.  The participant\n             will need a baseline test and a test to show that the PSA has increased.\n\n        Exclusion Criteria:\n\n          -  Histologic variants other than adenocarcinoma in the primary tumor\n\n          -  Patient with mCRPC who requires urgent treatment with docetaxel\n\n          -  Therapy with samarium, strontium or radium within 8 weeks prior to first dose of\n             study drug.\n\n          -  Prior radiation therapy completed < 3 weeks or single fraction of palliative\n             radiotherapy within 14  days prior to first dose of study drug.\n\n          -  Active or uncontrolled autoimmune disease that may require corticosteroid therapy\n             during study\n\n          -  Severely compromised immunological state, including known human immunodeficiency\n             virus (HIV)\n\n          -  Known acute or chronic hepatitis B or C\n\n          -  Chemotherapy and other investigational therapies (targeted or immunotherapy) will\n             require a 3-week washout period before treatment initiation"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146833", 
            "org_study_id": "KCP-330-007"
        }, 
        "intervention": {
            "arm_group_label": "selinexor", 
            "intervention_name": "selinexor", 
            "intervention_type": "Drug", 
            "other_name": "KPT-330"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "castrate-resistant prostate cancer", 
            "prostate cancer", 
            "Karyopharm", 
            "KPT-330", 
            "selinexor"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M.D. Anderson Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Christopher J Logothetis, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "John Araujo, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of Oral Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma", 
        "overall_contact": {
            "email": "johna@mdanderson.org", 
            "last_name": "John Araujo, M.D., Ph.D.", 
            "phone": "(713) 563-7203"
        }, 
        "overall_official": {
            "affiliation": "MDACC", 
            "last_name": "Christopher J Logothetis, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimate clinical benefit as characterized by stable disease (SD), partial response (PR), or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1", 
            "measure": "Estimate clinical benefit", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "PSA response rate determined by a 30% drop in PSA at 12 weeks compared to baseline", 
            "measure": "Estimate the prostate-specific antigen (PSA) response", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Karyopharm Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karyopharm Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}